Lipoproteins are removed from the plasma by LDL receptordependent and -independent pathways. The relative contribution of these has been established for LDL by using modified lipoproteins, but this has not been possible for apoE-rich lipoproteins, such as chylomicron remnants. To do this, we used a monospecific antibody to the rat LDL receptor. The antibody was injected intravenously into mice followed by '25I-lipoproteins. Blood samples were obtained sequentially and radioactivity measured to determine the plasma clearance of the lipoproteins. The animals were then sacrificed and the tissues removed, dried, and the radioactivity measured to determine tissue uptake. An albumin space was also measured to correct for blood trapping. With '25I-human LDL, -50% of the injected dose was cleared in 180 min. This was reduced to 30% by the antibody and this was identical to the disappearance of reductively methylated LDL. This is a lower estimate of LDLmediated uptake (40%) than in other species. LDL uptake per gram tissue was similar for the liver and the adrenal gland and was -50% LDL receptor-dependent in both tissues. With 125I-chylomicron remnants, clearance was much more rapid with -50% cleared in 5 min. By agarose gel electrophoresis, radioactivity was not transferred from chylomicron remnants to other lipoprotein classes. Chylomicron remnants with label on only apoB or in 3H-cholesterol esters showed a similar pattern. Combining the estimates of the three labeling procedures, -35% of the 30 s and 25% of the 5 min chylomicron remnant disappearance was LDL receptor dependent. The liver, per gram tissue, took up five times as much radioactivity as the adrenal gland. At 5 min, at least 50% ofthis was LDL receptordependent in liver and 65% in adrenal gland. We conclude that the LDL receptor plays a major, and somewhat similar quantitative role in the clearance of both LDL and chylomicron remnants in the mouse. However, at least in the mouse, non-LDL receptor-mediated lipoprotein clearance is quantitatively important and is also very rapid for chylomicron remnants. Thus, for chylomicron remnants, it can easily compensate for LDL
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Introduction
Because the discovery of a strong positive correlation between plasma LDL and the incidence of coronary heart disease (1), the determinants of the level of LDL in the serum have been studied intensively. The classic studies ofBrown and Goldstein identified a receptor on the surface of most cells (2) that initiates the uptake of intact plasma LDL particles into the cell via endocytosis, and thus plays a major role in maintaining cholesterol homeostasis. Although the receptor recognizes both apoB and apoE, it has a much greater affinity for apoE than apoB (3) . The number of receptors expressed on the surface of a cell is regulated by the cellular cholesterol content; LDL receptors are downregulated when substantial amounts ofcholesterol are delivered to the cells, thus preventing them from accumulating excess cholesterol (4). Quantitatively, the major site of LDL receptor-mediated lipoprotein degradation is the liver. However, even in the complete absence of LDL receptors, a large fraction of LDL continues to be taken up by hepatocytes (5) , indicating that there is at least one mechanism other than the LDL receptor that can play a role in the catabolism of LDL.
Furthermore, other lipoproteins, including chylomicron remnants, seem to have both LDL receptor-dependent and -independent mechanisms of transport (6) .
Chemically-modified forms of LDL, such as reductively methylated LDL (7) and 1,2-cyclohexanedione-modified LDL (8) , have been used to determine the relative contribution of LDL receptor-dependent and -independent pathways to LDL metabolism. However, it has been difficult to definitively separate the contributions of LDL receptor and non-LDL receptor-mediated transport for lipoproteins other than LDL. The development of an anti-LDL receptor antibody which specifically blocks the LDL receptor (9) allowed us to approach this problem. We have observed (10) that the degradation ofchylomicron remnants in isolated primary rat hepatocytes in vitro could be almost completely abolished by the addition of the anti-LDL receptor antibody, suggesting that processing ofchylomicron remnants by hepatocytes can be dependent upon the LDL receptor. These results are not entirely consistent with observations in Watanabe rabbits (11) and in patients with familial hypercholesterolemia (FH) (12) in which clearance of chylomicron remnants was rapid, although LDL receptors recent description (13) of an LDL receptor-related protein (LRP) that can bind lipoproteins that are enriched in apoE (14) and is not subject to down regulation by cholesterol provides a potential mediator of such an alternate pathway.
To directly examine the role of LDL receptor-dependent and -independent pathways to the plasma clearance and tissue uptake of chylomicron remnants in vivo, mice were injected with anti-LDL receptor antibody, and the plasma removal of subsequently injected lipoproteins was measured. The results suggest that the LDL receptor plays a major quantitative role in the clearance and tissue uptake ofboth LDL and chylomicron remnants in the normal mouse in vivo.
Methods
Animals. Female Swiss Webster mice, weighing 27-30 g, were purchased from Simonsen Laboratories and housed with a 12-h light cycle (7 am-7 pm) and free access to a standard mouse chow and tap water. Sprague-Dawley-derived rats from the same source were fed a standard diet until they were used as lymph donors.
Reagents. Radioiodine ('25I-carrier-free) was purchased from Amersham Corp., Arlington, IL, and tissue culture media were from Gibco, Grand Island, NY. Fatty acid-poor bovine albumin (BSA) were obtained from Behring Diagnostics, San Diego, CA. All other chemicals were obtained from Sigma Chemical Co., St. Louis, MO, or J. T. Baker Chemical Co., Phillipsburg, NJ.
Preparation oflipoproteins. Human LDL (d 1.0 19-1.063 g/ml) was isolated from EDTA-containing plasma by density gradient ultracentrifugation (15) and radiolabeled with Na '25I using Iodogen (22) . The acetylation and reductive methylation (RM) ofLDL were performed as described by Basu et al. (17) and Weisgraber et al. (18) , respectively. Dilactitol '25I-tyramine (DLT)-LDL was prepared using the method of Strobel et al. (19) . Chylomicrons were prepared by the method previously described (20) , and chylomicron remnants were prepared by the modification of the method of Redgrave and Martin (21) previously described (22) . Chylomicron remnants were radiolabeled using three different procedures. For most of the experiments, isolated chylomicron remnants were iodinated by a modification (22) of the iodine monochloride method (23) . In one group ofexperiments, chylomicron remnants were isolated from rats that had been injected with chylomicrons that had been previously radiolabeled by the iodine monochloride method. In another group of experiments, chylomicron remnants were labeled with 3H-cholesterol ester by the method of Fielding (24) . All lipoproteins were screened for biologic activity as described below. In addition, the degree oflipid iodination was monitored on all batches as previously described and fell within the range previously reported (22) . Selected batches were analyzed by PAGE in a system containing 0.5% SDS with or without autoradiography, and apoprotein contents and iodination patterns were similar to previously reported values (25) . Total protein concentration of lipoproteins was determined by the method of Lowry et al. (26) .
Anti-LDL receptor antibodies. The anti-LDL receptor antibodies used have been previously described and characterized (9, 27) . Monospecificity and lack of cross-reactivity with the LRP have been previously documented (27 (27) . The solubilized membranes (200 Mg) were separated on 6% polyacrylamide gels by the method of Laemmli (30) under nonreducing conditions. Immunoblotting for the LDL receptor was performed as previously described (9) . Briefly, proteins were transferred to nitrocellulose paper by blotting as described, and the portion ofthe paper containing the molecular weight standards was cut offand stained with 0.1% amido black. The remainder ofthe paper was incubated with 1 Mg/ml polyclonal anti-rat LDL receptor rabbit antiserum for 1 h at room temperature, washed, and then incubated with horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG. The HRP conjugated IgG was developed with the Immuno-Blotfm (GAR-HRO) assay kit (Bio-Rad Laboratories, Inc., Richmond, CA). The (22, 25) .
To functionally test the lipoproteins, they were incubated with mouse peritoneal macrophages. Specific degradation of both 125I-LDL and '251-chylomicron remnants could be demonstrated. As previously reported (31), chylomicron remnants were degraded at a slower rate than LDL; however, degradation of both LDL and chylomicron remnants were suppressed by > 70% by an excess ofunlabeled lipoproteins (not shown) or of anti-LDL receptor antibody (Fig. 1 a) . In contrast, the degrada- tion ofreductively methylated 1251I-LDL (RM-LDL) was significantly lower than 1251I-LDL ( Fig. 1 b) , indicating that the reductive methylation was effective in making the particles a poor ligand for the LDL receptor pathway. In addition, lipoproteins were screened for uptake by the acetyl LDL receptor. The uptake by these cells was low compared to acetyl LDL (not shown), was not blocked by an excess of unlabeled acetyl LDL ( Fig. 1 c) , but was blocked by the anti-LDL receptor antibody ( Fig. 1 a) receptor antibody was also examined. The degree ofinhibition was dependent upon the amount of antibody injected (Fig. 3) . The maximum effect was obtained with 0.5 mg per mouse. Injection of > 1.0 mg actually resulted in reduced blockade, therefore, 0.5 mg antibody was used in all subsequent experiments. The result that -40% of LDL uptake in the first 2 h in the mouse is dependent on the LDL receptor is somewhat lower than previous estimates with RM-LDL and autologous LDL in the rat (32) or rabbit (33) .
Effect of anti-LDL receptor antibody on LDL uptake by tissues. The specific tissue spaces of LDL were examined in several organs to assess the major tissue sites of LDL uptake in the mouse. After the final blood sample, the liver, adrenal gland, spleen, both kidneys and a piece of small intestine were removed and counted for radioactivity. The dry tissue weight was measured to reduce the variability due to the different amounts oforgan moisture. This was also corrected for nonspecific trapping of lipoproteins by subtracting the tissue space determined for albumin. The differences between the 1251-labeled LDL and the "25I-albumin spaces for each tissue are re- ferred to as "specific tissue spaces" (29) . DLT-LDL was used in these studies to minimize the amount of degradation that might have occurred, subsequent to endocytosis (34, 35) . The plasma clearance of DLT-LDL was identical to that ofconventionally-labeled LDL (not shown).
Liver and adrenal gland were the most avid in accumulating both native LDL and DLT-LDL as compared to spleen, kidney, and small intestine (Fig. 4) . By mass, the liver accounted for the uptake of 85% of the lipoprotein. It was somewhat surprising that the liver had a specific tissue space only slightly less than that of the adrenal. This might be due to the fact that, in the mouse, the adrenal is so small that we were unable to completely free it of surrounding adherent tissue, particularly fat. Consistent with this, immunoblots ofliver and adrenal with equal amounts ofapplied protein confirmed that, on a protein basis, the adrenal gland is about twofold richer than the liver in LDL receptors (Fig. 5) . After injection ofanti-LDL receptor antibodies, the specific tissue spaces of "23I-DLT-LDL were reduced in both the liver and adrenal gland and to a lesser extent, in the spleen, kidney, and small intestine. Based on the data in Fig. 4 , it was estimated that 45% of hepatic uptake and 55% of adrenal uptake of LDL was LDL receptordependent. These values are also lower than those obtained with RM-LDL in rat (32) and rabbit (33) . Taken together, these results suggest that the anti-LDL receptor antibody blocks LDL uptake, but may result in an underestimation ofthe contribution of the LDL receptor-dependent pathway.
Effect ofanti-LDL receptor antibody on the disappearance of'25I-chylomicron remnants from plasma. In agreement with other studies, '251-chylomicron remnants were removed from the plasma at a very rapid rate (20) . Due to the rapid disappearance, the initial plasma concentration was calculated based on the amount of chylomicron remnants injected, the estimated total blood volume and the percent loss ofinjected material, as determined in the LDL experiments. Using this to calculate the To radioactivity, -33% ofthe injected particles were removed in 0.5 min and 48% in 2 min (Fig. 6) . To examine the role ofthe LDL receptor in the removal of chylomicron remnants from the circulation, mice were first injected with the anti-LDL receptor antibody at a dose that was previously shown to maximally block LDL receptor-dependent clearance of LDL. At this concentration, the antibody reduced the very rapid (30 s) clearance to 25% and the 5 min clearance to 31% (Fig. 6 ). Based on this, at least 35% of the remnant disappearance could be attributed to the LDL receptor.
A significant portion of the radioactivity of the chylomicron remnants radiolabeled after isolation is located on proteins other than apoB. Although the time frame is very short, some of these might exchange in plasma with other lipoproteins; thus, it was possible that the radioactivity in plasma may represent labeled remnant apoproteins that had redistributed to other lipoproteins and not chylomicron remnants remaining in the circulation. To test this, plasma samples were analyzed after the injection of '25I-chylomicron remnants by agarose gel electrophoresis. If there was transfer of labeled apoproteins to other lipoproteins, their radioactivity would be associated with faster migrating lipoproteins that can easily be distinguished from chylomicron remnants which remain at the origin. Plasma samples were separated by agarose gel electrophoresis and autoradiograms prepared. The autoradiogram was purposely overexposed to reveal any radioactivity associated with nonchylomicron remnant lipoproteins. As expected, noninjected chylomicron remnants remained at the origin (Fig. 7 , lane 3). In plasma samples collected up to 4 min after chylomicron remnant injection, there was no significant transfer of labeled apoprotein to other lipoprotein classes (Fig. 7 , lanes 4-6). Also shown is the migration of labeled LDL (Fig. 7 , lane 1) and acetyl-LDL (Fig. 7, lane 2) for comparison. Because there is nonapoprotein protein on chylomicron remnants, particles containing a core label were also studied. Chylomicron remnants were labeled with 3H-cholesterol ester and their disappearance measured as above. Although the amount ofradioactivity that could be injected limited the accuracy of the study, the results were similar to those with iodinated chylomicron remnants. The clearance of 3H-cholesterol ester-labeled chylomicron remnants was rapid with -80% removed after 5 min and the plasma clearance was suppressed by the anti-LDL receptor antibody (Fig. 8) . To Fig. 4 except that chylomicron remnants were labeled with 3H-cholesterol ester. Each point represents the mean±SE. n = 8 for both remnants (-) and remnants + anti-LDL receptor antibody (o). *P < 0.05.
removal over a longer time period without the possibility of exchange of radiolabel, the removal of chylomicron remnants were prepared with the label primarily on apoB. This was done by labeling chylomicrons with 1251, injecting these particles into eviscerated rats and isolating remnants. In these particles, > 80% ofthe radioactivity was on the nonexchangable apoB as assessed by radioautography of polyacrylamide gels (not shown). The clearance of these particles was similar, although somewhat more complete than that ofin vitro labeled particles. After 1 h, at least 25% ofremnant disappearance was still due to the LDL receptor (Fig. 9) . The kinetics ofclearance ofremnants is somewhat complex and does not obey a single process kinetic model (not shown). With this preparation, the time for removal of 50% ofthe particles was -7 min in control and -21 min in antibody-treated mice, consistent with the LDL receptor playing a major role in their clearance. It should be noted, however, that even in the antibody-treated mice, remnant clearance was much more rapid than LDL clearance and by 1 h, b completion in both groups. This sugges receptor clearance pathway (6) iad proceeded to near way can remove most of a bolus of remnants in a relatively its that the non-LDL short time. igher affinity for remEffect ofanti-LDL receptor antibody on chylomicron remtor-independent pathnant uptake by tissues. The liver, adrenal glands, spleen, kidney, and a piece of small intestine were removed and counted for radioactivity 5 min after the injection of chylomicron remnants. In contrast to LDL, the specific 125I-chylomicron rema Remnants nant tissue space in the adrenal gland was significantly lower -Anti-LDL R Ab than that in the liver (Fig. 10) . The injection of anti-LDL receptor antibody blocked the uptake of '25I-chylomicron remnants in the liver, adrenal gland, and spleen by at least 50% at the 5-min timepoint. This was similar to its effect on LDL uptake and suggests that the LDL receptor normally plays a major quantitative role in the rapid removal of chylomicron remnants in these tissues that is similar to that for LDL. However, in the 1-h clearance experiment of Fig. 9 , the remnant space in the liver of antibody-treated animals was now only blood much more rapidly than LDL; second, the particles are ). Effect of anti-LDL receptor antibody on clearance of 1231.
removed by the liver almost exclusively (39), even though the icron remnants from the blood of mice in vivo over the long adrenal gland has a higher density ofLDL receptors (29) ; third, o study remnant removal over a longer time period without earlier studies from this laboratory (22) found normal uptake ;ibility of exchange of radioactivity, chylomicron remnants a .n.i 1pared from '251-chylomicrons. These particles have most of by the perfused lver ofrats fed an atherogec dlet, a condlton oactivity in apoprotein B. The protocol was the same as dein which the LDL receptor is moderately downregulated; in Fig. 2. (a) Entire time course; (b) first 6 min only. Each fourth, the Watanabe rabbit, which has a defective LDL receppresents the mean±SE. n = 4 for remnants (o) and n = 6 for tor, removes chylomicron remnants rapidly (11) and fifth, huts + anti-LDL receptor antibody (v). *P < 0.05. hypertriglyceridemic or hypercholesterolemic after a fat-containing meal.
To assess the role ofthe LDL receptor in chylomicron remnant removal, it was necessary to create an acute blockade of LDL receptor function because in any chronic model, such as a receptor-deficient rabbit, compensatory changes could occur, and the expansion of endogenous lipoprotein pools makes even simple kinetic studies difficult to interpret. The mouse was chosen because its small blood volume allowed us to achieve high antibody concentrations without the need for prohibitive amounts of antibody. Lipoprotein metabolism in the mouse has not been studied in the same detail as in several other species, such as rats, rabbits, and humans. However, the mouse has analogous lipoproteins and apoproteins to these species (40, 41) , including apoAI, AII, B, C, and E, it has a receptor similar to the LDL receptor which recognizes both apoB and apoE (37) , and it seems to be a reasonable model because no unusual metabolic features have been identified. The limitations of this study, caused by the small size of the animals, were that with 3H-cholesterol ester-containing particles, it was difficult to quantify the radioactivity in the later blood samples, and it was difficult to free the adrenal gland of all adherent tissue. The latter may account for the finding that LDL uptake per gram tissue dry weight was similar in liver and adrenal, whereas in most other species the adrenal is richer in LDL receptors. In fact, on immunoblots, when similar amounts of protein are applied, the adrenal gland appears to have a greater amount of LDL receptor than liver, although this difference may not be as great as in some other species. Nonetheless, because the same protocol was used with the two lipoprotein types in these studies, the relative difference between hepatic and adrenal tissue spaces with LDL and chylomicron remnants still remains.
In addition, the use of human LDL and rat chylomicron remnants represents a compromise; the use of homologous lipoproteins was not feasible because of the limited blood volume of the mouse. In previous cell culture studies from this laboratory (38) , human LDL had only a slightly lower affinity for the rat LDL receptor than rat LDL; however, in in vivo studies by Dietschy and colleagues (32) , there was a greater degree of LDL receptor-mediated uptake ofrat lipoproteins in rat than of human lipoprotein in that species. This may be due to an ability of the rat particles to acquire apoE. Thus, our choice of lipoproteins may account for some of the quantitative differences between this study and those in the rat (32) .
The antibody used has previously been thoroughly characterized (9, 10, 27) . It does not cross-react with the LRP or other proteins and inhibits uptake of both apoB-and apoE-containing lipoproteins in rat and murine cells. In general, on Western blots of noninduced liver, the liver receptor, its dimer, and a precursor are seen. Smaller bands are probably degradation products. All bands are induced by ethinyl estradiol treatment and react with a monoclonal anti-LDL receptor antibody (27) . Interestingly, whereas it completely inhibits chylomicron remnant and fl-VLDL uptake in fibroblast (37) and tumor lines (10), it is only 80-90% effective in macrophages (37) and hepatic cells (10). A dose-response experiment of LDL clearance with antibody showed an increase in blockade with up to 0.5 mg antibody injected and then, a paradoxical fall. This amount should provide an antibody concentration of 180 Ag/ml. Based on available information, this is roughly comparable on a protein basis to the apoB content of mouse blood. Because the antibody is a more potent competitor for LDL receptor binding than LDL, the antibody is probably present in excess of LDL, but perhaps not an adequate excess to completely compete for LDL uptake. Because apoE is a higher affinity ligand than apoB, the degree of blockade of apoE-mediated uptake may be less than that of apoB-mediated uptake. This may be somewhat mitigated by the fact that the endogenous apoE level is relatively low. Thus, because the blockade may not be complete, the contribution of the LDL receptor to the removal of the two types of particles estimated by this method should be taken as a minimum value. For LDL, the estimates that 35% of plasma disappearance, 45% ofliver uptake, and 55% ofadrenal uptake is due to the LDL receptor are lower than those that have been obtained in other species using labeled residualized homologous LDL and RM-LDL. The discrepancy between tissue uptake and plasma clearance suggests that either the estimate of initial concentration was inaccurate or there was some sequestration of particles. The latter possibility which could include some macrophage uptake seems quite plausible. Estimates for LDL receptor-mediated LDL removal from plasma in humans have been 67-80% (42) ; in the rabbit, 62-76% (33); and in the rat, 57-75% (32) . Interestingly, in our study, RM-LDL clearance gave the same estimate of receptor-mediated uptake as did antibody blockade. In general, adrenal has had the highest per gram receptor-mediated uptake and the liver, second (29, 32) . Taken was seen at the 30-s timepoint. Further, even though the liver had a higher "specific space" than the adrenal gland, this was due to an increase in the LDL receptor's contribution in proportion to the LDL receptor-independent contribution, suggesting that some factor other than LDL receptor density is responsible for the tissue distribution of uptake. This could be due simply to the size ofthe fenestrations in the space ofDisse, allowing chylomicron remnants access to the hepatic LDL receptor and not to adrenal LDL receptors. Although the LDL receptor appears to play a major role in remnant removal, the non-LDL receptor pathway(s) also plays a substantial role and can fully compensate for the LDL receptor when it is blocked by the anti-receptor antibody. Thus, even in the blockaded animal, the disappearance ofremnants is much more rapid than that of other lipoproteins and is almost complete in < 1 h. This can explain the data of Rubinsztein et al. (12) who did not find a marked impairment of remnant removal in patients with receptor-negative familial hypercholesterolemia. In that study, the total serum and chylomicron remnant response to oral retinyl palmitate was only modestly (-20%), and not significantly greater in FH than in normal patients. In contrast, patients who were homozygous for apo E-2 had markedly greater responses as would be expected if both removal mechanisms relied primarily on apo E as the recognition signal. A role for the LDL receptor is further supported by the observation that remnant removal is accelerated by estrogen treatment which increases LDL receptor (43), but not LRP (unpublished observation) levels.
This, then, leaves open the question of the nature of the remnant removal mechanism when the LDL receptor is absent, defective, or downregulated. A simple hypothesis is that the recently-described LRP (13) provides the secondary pathway. Although it has been shown that this protein does bind apoE and apoB (14) and can initiate internalization (44) , compared to the LDL receptor, at least in cell culture, it does so with a lower affinity and requires further enrichment ofalready apoE-rich particles with additional apoE (45, 46) . Thus, under conditions where this was the only receptor operative, LDL clearances might be markedly delayed whereas, even though remnant clearance was slower than normal, it could still be quite rapid by comparison to normal LDL removal. This would also explain why the remnant removal curves are not more divergent at later time points. If remnant removal by LDL receptor has a T112 of 30 s and non-LDL receptor of 90 s (threefold difference), in a perfect experiment, after 4.5 min, 99% would be cleared by the LDL receptor and 88% by the non-LDL receptor pathway. Because there is some exchange and some slowly removed, or even resecreted radioactivity, this would account for the plateau and narrowing differences seen at the later timepoints. The disparity between the two particles would be further exaggerated ifthe ability to acquire additional apoE is required for binding because remnants are good substrates for apoE acquisition, whereas LDL does this poorly and in the case ofhumans, perhaps not at all. Further testing ofthis hypothesis will require complementary studies to these with an anti-LRP antibody or studies in LRP-deficient animals, ifsuch can be found.
